Canaccord Genuity rated Buy Ym Biosciences, Inc. (AMEX: YMI) on 03/26/2012, when the stock price was $1.85. Since then, Ym Biosciences, Inc. has gained 58.92% as of 02/08/2013's recent price of $2.94.
If you would have followed this Canaccord Genuity's recommendation on YMI, you would have gained 58.91% of your investment in 319 days.

YM BioSciences Inc. is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. The Company owns or in-license substances or products in order to advance them along the regulatory and clinical pathways toward commercial approval. The Company?s portfolio of products in active clinical development includes one anti-cancer agent (a monoclonal antibody) in a number of clinical trials targeting more than 10 different tumors and/or stages of cancer, and an inhalation-delivery approach for fentanyl to treat acute pain, including cancer pain. The Company?s two product candidates in the clinical stage of development, as of June 30, 2009, were NIMOTUZUMAB and AeroLEF. Its three additional products licensed that are not in clinical development include Tesmilifene and two anti-cancer vaccines, a TGFα vaccine and a HER1-targeting vaccine.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.

Marked as spam